7 march 2018
4.30 PM - 9.00 PM
- Why is the Nordic region a center for global life sciences activity?
- How is the Nordic investment community evolving to guide life sciences companies to publicly list?
- Will the growing number of public listings of life sciences companies attract more global venture capital investment to the region?
- What do the licensing and collaboration transactions look like that often underpin companies contemplating a listing?
- How are the public listings that are getting done being planned and structured?
How to navigate the listing process
The past few years have witnessed a growing number of Nordic life sciences companies tap the capital markets of Copenhagen, New York and Stockholm.
The paradigm for how Nordic life sciences companies have traditionally achieved financial exits for their investors in this region is changing, with more companies today seeking to publicly list their shares, sometimes even on more than one stock exchange. How are the life sciences capital markets working today, and what can be done to best prepare a Nordic life sciences company for a public listing?
This seminar, with contributions from leading industry experts, will examine the critical issues that executive management teams at life sciences companies must contemplate in advance of a public listing. We will also examine key licensing and collaboration structures and transactions that are often put in place in advance of and in support of successful public offerings.
There is no fee to attend, but space is limited.
A full list of speakers and their bios will be shared in the coming weeks.
Speakers include the CEOs of Nordic life sciences companies that have gone through the listing process, local and foreign investors that have supported their growth and strategies, and representatives from Big Pharma who are often instrumental in leading licensing and collaboration transactions with pre- and post-listed companies.
4.30 PM - 5.00 PM: Registration
5.00 PM - 5.45 PM: Session 1
5.45 Pm - 6.00 PM: BREAK
6.00 PM - 6.45 PM: Session 2
6.45 PM onwards: Reception
Wednesday 7 march 2018
Amerika Plads 37
DK - 2100 Copenhagen
About Dechert LLP
Dechert is a leading global law firm focused on sectors with the greatest complexities and highest regulatory demands. Life sciences industry leaders rely on Dechert’s top-ranked practice to understand the business opportunities and challenges they face and deliver practical commercial insight and judgment. We offer a range of transactional, regulatory and dispute resolution services to life sciences companies around the world and at all stages of growth. Whether guiding a start-up biotech firm through its first round of funding, licensing a medical device company’s patents or winning antitrust, securities or patent disputes, we approach each matter with the resources of a major international firm and the focus and depth of a boutique.
Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion.
Plesner is a leading Danish law firm with leading specialist lawyers covering all aspects of the life science industry. While maintaining tier 1 rankings within all relevant practice areas, we are committed to continuous development to further our sector expertise and remain at the forefront of legal and technological innovation. Our approach is characterised by a joint and collaborative approach from our IP, regulatory, transactional and dispute resolution practices, we deliver market leading advice to the full range of life science clients from early stage biotech companies to the largest pharmaceutical companies.